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To characterize the distribution of nontuberculous 
mycobacteria (NTM) species isolated from pulmonary 
samples from persons in Asia and their association 
with pulmonary infections, we reviewed the literature. 
Mycobacterium avium complex bacteria were most 
frequently isolated (13%–81%) and were the most common 
cause of pulmonary NTM disease (43%–81%). Also 
pathogenic were rapidly growing mycobacteria (M. chelonae, 
M. fortuitum, M. abscessus). Among all NTM isolated from 
pulmonary samples, 31% (582/1,744) were considered 
clinically relevant according to American Thoracic Society 
diagnostic criteria. Most patients were male (79%) and had 
a history of tuberculosis (37%). In Asia, high prevalence of 
rapidly growing mycobacteria and a history of tuberculosis 
are distinct characteristics of pulmonary NTM disease. This 
geographic variation is not well refl ected in the American 
Thoracic Society criteria for NTM infections and could be 
incorporated in future guidelines.
Nontuberculous mycobacteria (NTM) are common in the environment and have been isolated worldwide (1). 
They are increasingly recognized as pathogens in humans. 
Pulmonary disease is the most common manifestation (2) 
and is thought to result from aerosol inhalation. Because of 
their omnipresence in the environment, isolation of NTM 
from the respiratory tract does not, per se, indicate NTM 
disease. Therefore, the American Thoracic Society (ATS) 
has established diagnostic criteria to help distinguish 
between contamination and true NTM disease (1).
Although NTM are present worldwide, much of 
the literature on pulmonary NTM disease comes from 
industrialized countries, mainly Europe, North America, 
and Japan. Differences in the NTM species distribution in 
clinical samples and disease have been noted among these 
regions (3); by extrapolation, these characteristics in other 
parts of the world probably differ as well.
Asia has a long history of NTM research, both 
clinical and fundamental. Tsukamura et al. have reported 
on pulmonary NTM infections in Japan dating back to 
the early 1970s (4). Yet because many studies were not 
reported in English, knowledge of the distribution of NTM 
species in Asia is limited. However, these data will enhance 
our understanding of NTM diversity between and within 
species and their association with NTM disease in humans. 
For this reason, we searched the literature on clinical NTM 
isolation and disease from different regions in Asia and 
compared our fi ndings with previously published data from 
other regions.
Literature Search
From March 2009 to December 2009, we searched 
PubMed (www.ncbi.nlm.nih.gov/pubmed) for English-
language articles about nontuberculous mycobacteria in 
Asia. The search strategy was as follows: “mycobacteria, 
atypical” [MeSH] AND “Asia” [MeSH] OR “atypical 
mycobacterium infections” [MeSH] AND “Asia” [MeSH]. 
We chose the term Asia to incorporate the following 
countries: Brunei, Cambodia, East Timor, Indonesia, 
Lao People’s Democratic Republic, Malaysia, Myanmar, 
Philippines, Singapore, Thailand, Vietnam, Bangladesh, 
Bhutan, India, China, Hong Kong, Japan, South Korea, 
Mongolia, and Taiwan.
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We found 256 citations. If we considered the abstract 
to be relevant, we obtained a full copy of the article; we 
contacted authors if full-text articles could not be retrieved. 
Furthermore, the reference sections were screened for 
other eligible citations. We considered 67 articles to be 
relevant, of which 37 were excluded for the following 
reasons: 11 were case reports, 7 referred to disseminated 
NTM infections, 6 were not in English (5 in Japanese, 1 
in Chinese), 6 did not concern pulmonary NTM, 4 were 
reviews, and 3 represented neither epidemiologic data nor 
clinical cases. From the remaining 30 articles (4–33), the 
following data were abstracted for this review: country, 
research setting, NTM species, clinical features of the 
patients, and radiographic data. All articles were screened 
to determine whether ATS diagnostic criteria for the 
determination of clinical relevance of NTM isolations 
applied (1). Cases consistent with the ATS diagnostic 
criteria were considered clinically relevant.
Search Results
We identifi ed 30 English-language articles about the 
epidemiology and clinical relevance of NTM isolates in 
Asia (4–33). We found data from China (5), Hong Kong 
(6), India (7–13), Japan (4,14–20), South Korea (21–24), 
Singapore (25), Taiwan (26–29), and Thailand (30–33). 
Most articles used a combination of methods to identify 
NTM species. Biochemical and phenotypic analysis (n = 
11) were used most frequently, followed by molecular tools 
(n = 4) or a combination of both (n = 5). From 10 articles, 
the exact methods of species identifi cation could not be 
determined. The use of identifi cation methods differed over 
time; biochemical and phenotypic analyses were mostly 
used during 1966–1990 (6 of 7 studies), whereas use of 
molecular tools increased during 1990–2009 (Table 1). The 
number of different species isolated did not differ between 
the 2 periods. However, most species identifi cation by 
biochemical testing depended heavily on 1 study from 
India (11).
Epidemiology
Regardless of clinical relevance, 25 articles reported 
on NTM isolates from pulmonary samples (Figure 1) 
(4–13,17–22,25–33). In general, Mycobacterium avium 
complex (MAC) was most frequently (67%) isolated, 
although it predominated in northeastern Asia (South Korea 
and Japan). Exact species identifi cation of MAC (now M. 
avium, M. intracellulare, M. chimaera, M. colombiense, M. 
vulneris, M. marseillense, M. bouchedurhonense, and M. 
timonense) (34,35) was not performed, thereby hampering 
a more detailed analysis.
Rapidly growing mycobacteria ([RGM] M. fortuitum 
complex, M. abscessus, M. chelonae) were frequently 
identifi ed in pulmonary samples from Taiwan, China, 
and Singapore (5,25–29). The overall isolation of RGM 
in this part of Asia was 16%, making RGM the second 
most frequently isolated species in this region. Other 
species frequently encountered were M. kansasii (4%) and 
M. gordonae (3.5%). M. malmoense, a species regularly 
encountered in northwestern Europe, was found only 9 
times in a single study of 1,000 NTM isolates from India 
(11). Also, M. xenopi, which is frequently encountered in 
Canada and England (3), was isolated only 10 times (of 
11,987 isolates) and mainly during studies from India 
(7,11,13,21,27).
Clinical Relevance
The clinical relevance of pulmonary NTM isolates 
(Table 2) was mentioned in 10 articles covering a total of 
1,744 patients (6,16,21,23,25,28–30,32,33). No articles 
covered the clinical relevance of NTM in China. Different 
criteria were used to defi ne clinical relevance, but all 
criteria comprised a combination of clinical, bacteriologic, 
and radiographic criteria. Only 4 studies reported a priori 
use of ATS criteria (1). According to ATS criteria, for 31% 
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Table 1. Nontuberculous mycobacteria isolated in Asia, 1971–
2007*
Species
Before 1990  
(n = 1,205)† 
After 1990  
(n = 7,614)† 
Mycobacterium abscessus – X
M. aichiense X –
M. asiaticum X –
M. avium complex X X
M. celatum – X
M. chelonae X X
M. flavescens X X
M. fortuitum X X
M. gastri X X
M. gordonae X X
M hemophilum X –
M. kansasii X X
M. malmoense X –
M. marinum X X
M. neoarum X –
M. parafortuitum X –
M. phlei X X
M. scrofulaceum X X
M. simiae X X
M. smegmatis X X
M. szulgai X X
M. terrae X X
M. tokaiense X –
M. triviale X X
M. thermophilum X –
M. thermoresistibile X –
M. ulcerans X –
M. vaccae X X
M. xenopi X X
*Data derived from references 4–33. X, isolated; –, not isolated. 
†Proportions of identification methods used (biochemical:molecular) 6:1 
before 1990, 5:8 after 1990.  
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(582/1,744) of patients, pulmonary NTM isolates were 
considered clinically relevant. Relevance varied widely 
across regions and studies. For example, a study of patients 
in an intensive care unit in Taiwan found that only 9% of 
NTM isolates were clinically relevant (28); however, in a 
study of HIV-infected patients in Thailand, relevance rose 
to 76% (30).
Figure 2 shows the distribution of mycobacterial 
species among patients with defi nite pulmonary NTM 
disease in Asia, according to ATS criteria. MAC was the 
most frequently reported (68% of all cases) cause of NTM 
disease; RGM were second (14% of all cases). Prevalence 
of RGM pulmonary infections ranged from 2.6% (Japan) 
to 44% (South Korea). M. malmoense and M. xenopi were 
not reported as causative species in any of these studies in 
Asia.
We found some discrepancies between isolation 
frequency (Figure 1) and clinical relevance (Figure 2). 
For example, in Hong Kong M. gordonae was found 
in 19% of pulmonary isolates regardless of clinical 
relevance but in only 4% of cases of pulmonary NTM 
infection. In contrast, in India, higher prevalence of M. 
szulgai was found (1% in all pulmonary samples vs. 
7% of all causes of pulmonary NTM). We therefore 
investigated the clinical relevance of the various NTM 
species separately, measuring clinical relevance per 
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India 
(n = 1,125) 
20% M. avium complex 
11% M. terrae 
10% M. scrofulaceum 
  7% M. flavescens 
  6% M. gordonae 
Thailand 
(n = 161) 
41% M. avium complex 
17% M. kansasii 
12% M. scofulaceum 
  6% M. fortuitum 
  4% M. gordonae 
China 
(n = 122) 
20% M. chelonae 
18% M. gordonae 
14% M. abscessus 
13% M. avium complex 
10% M. terrae 
Hong Kong 
(n = 168) 
19%     M. gordonae
15%     M. terrae 
12%     M. fortuitum 
   5%    M. chelonae 
   0.6% M. kansasii 
Singapore 
(n = 23) 
39% M. avium complex 
26% M. kansasii 
17% M. fortuitum 
  9% M. chelonae 
  4% M. abscessus 
Japan 
(n = 2,820) 
81%    M. avium complex 
10%    M. kansasii 
  3%    M. gordonae 
  3%    M. fortuitum 
  0.8% M. chelonae 
Taiwan 
(n = 440) 
42% M. avium complex 
18% M. abscessus 
13% M. chelonae 
11% M. kansasii 
 9% M. fortuitum 
South Korea 
(n = 7,128) 
73% M. avium complex 
  8% M. fortuitum 
  6% M. chelonae 
  3% M. gordonae 
2% M. kansasii
Figure 1. Five most prevalent nontuberculous 
mycobacteria species found in respiratory 
specimens, regardless of clinical relevance, Asia, 
1971–2007. Data from (4–13,17–22,25–33).
Table 2. Clinical relevance of NTM species isolated from pulmonary samples collected in Asia, by country, 1971–2007* 
Study area 
No.
patients
Patients for whom NTM 
infection was considered 
clinically relevant, % Criteria used (year of revision) Reference 
Hong Kong  168 17 ATS criteria (1990) (6)
Japan 357 76† ATS criteria (1997) (16)
South Korea 794 17 ATS criteria (1997) (21)
South Korea 23 65‡ BTS criteria (1999) (23)
Singapore 23 65 Compatible signs and symptoms, >3 positive sputum specimens, 
and radiographic features of recent lung disease 
(25)
Taiwan 111 9 ATS criteria (1990) (28)
Taiwan 169 28§ NTM in >2 samples, new radiographic lesions ,and no other 
pathogens (definite) or other concomitant bacteria (probable NTM) 
found 
(29) 
Thailand 33 76 NTM in sample(s); compatible signs, symptoms, and radiographic 
features; and no other explanation 
(30)
Thailand 24 29 Continued NTM isolation, progressive pulmonary disease, and 
worsening radiographic lesions 
(32)
Thailand 42 71 Repeated isolation of high numbers of NTM and presence of 
compatible disease process 
(33)
*NTM, nontuberculous mycobacteria; ATS, American Thoracic Society (1); BTS, British Thoracic Society. 
†Only Mycobacterium avium complex bacteria were included in this study.  
‡Only M. kansasii was included. 
§14% if only definite NTM were included.
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species by the percentage of patients meeting ATS criteria 
(Figure 3). Most clinically relevant species were MAC 
(56%), followed by M. abscessus (35%) and M. chelonae 
(31%). M. fortuitum, M. gordonae, and M. terrae were 
infrequently reported (1%–3%) as clinically relevant. 
The varying clinical relevance per species might partially 
explain the differences between Figure 1 and Figure 2.
Clinical Signs and Radiographic Features
We found information on clinical signs for 689 
patients and radiographic data for 1,044 patients (10,12,14–
16,20,21,23–25,27–30,33).  Most patients with pulmonary 
NTM infections were male (543/689). Because of 
incomplete data, mean age could not be calculated; 8 studies 
reported mean ages of 50–70 years. Other characteristics 
are shown in Table 3. One third of patients had a history 
of tuberculosis (TB) (252/689). HIV co-infection was 
less prevalent among patients with localized pulmonary 
NTM infections (15/280). Clinical signs of NTM disease 
mimicked those typical of TB: most frequently chronic 
cough (255/268), followed by hemoptysis (82/268), fever 
(47/268), and weight loss (40/268). Radiographically, most 
patients had structural lung disease; 39% (405/1,044) had 
cavitations and 44% (461/1,044) had bronchiectasis.
Discussion
NTM isolation and disease in Asia have several 
features. First, a substantial percentage (31%) of patients 
from whom pulmonary NTM were isolated had clinically 
relevant NTM disease. This fi nding is similar to the 33% 
and 25% found in studies in Canada and the Netherlands, 
respectively (2,3). In Asia, NTM may cause substantial 
pulmonary disease; differences in clinical relevance exist 
among species (Figure 3), as previously observed (2).
Second, MAC was the main cause of pulmonary NTM 
infection (68% of cases) in Asia. In a key article in 2002, 
Marras and Daley reviewed the prevalence of pulmonary 
NTM disease in the world (3). They noted a predominance 
of MAC among the causative agents of pulmonary NTM 
disease in Asia. Data from Asia were, however, scarce, 
and their conclusion was mainly based on 1 study (6). Our 
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India 
(n = 15) 
40% M. fortuitum 
33% M. kansasii 
20% M. triviale 
  7% M. szulgai
Thailand 
(n = 132) 
43% M. avium complex 
17% M. kansasii 
  8% M. scrofulaceum 
  5% M. fortuitum 
  5% M. chelonae 
Hong Kong 
(n = 28) 
54% M. avium complex
14% M. chelonae 
  4% M. kansasii 
  4% M.  szulgai 
  4% M. gordonae 
Singapore 
(n = 15) 
60% M. avium complex 
27% M. kansasii 
  7% M. chelonae 
  7% M. scrofulaceum 
Japan 
(n = 1,064) 
81%    M. avium complex 
14%    M. kansasii 
  2%    M. fortuitum 
  0.6% M. chelonae 
  0.5% M. szulgai 
Taiwan 
(n = 302) 
43% M. avium complex 
19% M. abscessus 
10% M. chelonae 
10% M. fortuitum 
 9% M. kansasii 
South Korea 
(n = 131) 
50% M. avium complex
39% M. abscessus 
  4% M. kansasii 
  3% M. fortuitum 
  2% M. chelonae 
Figure 2. Five most common nontuberculous 
mycobacteria species causing pulmonary 
infections, Asia, 1971–2007. Data from 
(4,6,10,13,17,19,21,25,27–33).
Table 3. Clinical and radiographic characteristics for patients with 
pulmonary nontuberculous mycobacteria infections in Asia, 
1971–2007* 
Characteristic No. (%) patients 
Concurrent conditions, n = 689 
 Malignancy, hematologic or solid 79 (11) 
 Gastrointestinal disease 40 (6) 
 HIV infection, n = 280 tested 15 (5) 
 Chronic corticosteroid treatment 18 (3) 
 Diabetes mellitus 18 (3) 
 Renal disease 13 (2) 
Previous lung disease, n = 689 
 Tuberculosis  252 (37) 
 Chronic obstructive pulmonary disease  62 (9) 
 Bronchiectasis 47 (7) 
Clinical signs, n = 268 
 Chronic cough 255 (95) 
 Hemoptysis 82 (31) 
 Fever 47 (18) 
 Weight loss 40 (15) 
Radiographic findings, n = 1,044 
 Cavitation 405 (39) 
 Nodular 559 (54) 
 Bronchiectasis 461 (44) 
*Data from (10,12,14–16,20,21,23–25,27–30,33).
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study supports their conclusion of the predominance of 
MAC in Asia, which is consistent with its predominance in 
other parts of the world, namely, North America and most 
parts of Europe (3).
Third, we found that in some regions in Asia, RGM 
are a major cause of pulmonary NTM disease. This fi nding 
contrasts with studies of NTM in other parts of the world 
(3). In a surveillance study from the Netherlands for 
instance, RGM caused only 3% of all pulmonary NTM 
infections (2). In the United States, this percentage is ≈5% 
(36). In the present review, RGM was found to generally 
cause 14% of pulmonary NTM infections, but in 3 
countries (India, Taiwan, South Korea) this percentage rose 
to >30% of infections. The fact that RGM were frequently 
found in pulmonary samples (Figure 1) could refl ect higher 
environmental exposure of RGM in Asia and, hence, higher 
isolation frequency. The predominance of RGM species 
may be the result of laboratory practices as well. Ethnic 
factors may also contribute to susceptibility to different 
species; i.e., Asian persons could be more susceptible to 
RGM infection.
Contrary to the high frequency of isolation of RGM 
species, M. malmoense and M. xenopi, frequently seen 
in other parts of the world, were not seen as causative 
species in any of the studies from Asia. M. xenopi has 
been associated with hot water systems (1); as a result, it 
might be expected to be more rare in Asia, where the water 
delivery infrastructure is less developed than that in Europe 
and North America.
A fourth feature of pulmonary NTM disease in Asia—
compared with Europe and North America—was the 
relatively high percentage of patients with a history of TB. 
This fi nding might merely refl ect the higher incidence of 
TB in Asia, or it could refl ect higher clinician awareness 
in Asia, such that physicians order Mycobacterium spp. 
cultures in former TB patients with coughing and hence fi nd 
a relatively higher number of NTM isolates. Alternatively, 
it could refl ect a true predilection of NTM for patients 
with structural lung disease (1) associated with a higher 
susceptibility to mycobacterial infection in general. The 
role of TB in the pathogenesis of pulmonary NTM disease 
is controversial; structural lung damage by a TB infection 
renders the host vulnerable to NTM disease (1), but there 
are also clues that exposure to TB infers cross-protection to 
NTM disease (37).
Our study has some limitations. The major limitation 
is the language restriction. The inclusion of languages other 
than English would probably have increased precision. 
For instance, during our literature search we came across 
5 articles, published as abstracts in PubMed, on NTM 
infections in Japan. Although certain aspects of these data 
were already published in the English-language articles 
we included, we did not have the means to include these 
non–English-language studies. Nevertheless, our study 
illustrates the distribution of NTM infections from different 
geographic areas in Asia and will increase knowledge of 
the distribution and relevance of NTM species in Asia.
Another limitation is the long time span of the included 
studies. Because they ranged from 1969 to 2008, they 
used different decontamination, culture, and identifi cation 
methods. Data should therefore be considered with caution 
because of the variety of laboratory procedures used by the 
several authors to isolate and identify NTM. First, different 
sample decontamination protocols may determine the 
yield of NTM by selecting for certain NTM species and 
inhibiting others (38). Second, the introduction of more 
sensitive liquid media probably increased NTM isolation 
and perhaps selected for specifi c species (26). Finally, and 
foremost, the major differences in identifi cation methods 
used in the studies introduce important biases. Because 
the taxonomy of NTM has been changing in recent years 
(37,39,40), the different NTM identifi cation methods used 
in the various studies might have infl uenced our results; use 
of molecular tools to identify the historical isolates would 
probably result in different, more detailed, identifi cations, 
especially among the MAC, the M. simiae group, and the 
RGM (37,39,40). We did note increased use of molecular 
tools for NTM identifi cation over time (Table 1), which 
will, over the next few years, provide us with a more up-to-
date overview of NTM species distribution in Asia.
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
56%M.aviumcomplex (438/776)
35%M.abscessus(60/170)
31%M.chelonae(15/48)
17%M.kansasii (34/198)
M.scrofulaceum(6/35)
9%M.celatum (1/11)
6%M.szulgai (2/33)
3%M.fortuitum
(8/262)
2%M.
gordonae
(2/125)
1%M.terrae(1/75)
Figure 3. Clinical relevance of pulmonary nontuberculous 
mycobacterium (NTM) isolates, Asia, 1971–2007. Relevance per 
species was defi ned as percentage of patients with pulmonary 
NTM isolates meeting the American Thoracic Society criteria. 
Species reported infrequently, i.e., <5×, are not shown. Data from 
(6,16,17,21,23,25,29,32,33).
SYNOPSIS
In conclusion, despite the limitations of language 
and species identifi cation methods, we have described 
the scale of human pulmonary NTM infections in eastern 
Asia. MAC bacteria were not only the most prevalent 
NTM found in pulmonary samples, but they were also the 
most common cause of pulmonary NTM disease in this 
geographic region. Distinct epidemiologic and clinical 
characteristics of pulmonary NTM disease in Asia were 
found: many patients had a history of TB, and RGM were 
a frequent cause of pulmonary NTM infections. These 
distinct characteristics of pulmonary NTM disease in this 
part of the world are not well refl ected in the current ATS 
criteria on NTM infections and could be incorporated in 
future guidelines.
Dr Simons is a resident in pulmonary medicine at the 
Radboud University Nijmegen Medical Centre. His primary 
research interest focuses on resistance mechanisms in multidrug-
resistant tuberculosis.
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